{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhang Y"],"funding":["hunan provincial science and technology department"],"pagination":["245"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8525046"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(1)"],"pubmed_abstract":["<h4>Background</h4>The combination of bevacizumab and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) could prolong progression-free survival (PFS) in patients with EGFR-mutant advanced non-small-cell lung cancer (NSCLC). Our study investigated the clinical and molecular factors that affect the efficacy of first-generation EGFR-TKI with or without bevacizumab and identify the subset of patients who can benefit from combination therapy.<h4>Methods</h4>Our study included 318 patients with EGFR-mutant locally advanced/advanced NSCLC treated with either first-generation EGFR-TKI combined with bevacizumab (A+T; n = 159) or EGFR-TKI monotherapy (T; n = 159). Two nomogram models to predict PFS and overall survival (OS), respectively, were constructed using two factors that"],"journal":["BMC medicine"],"pubmed_title":["Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC."],"pmcid":["PMC8525046"],"funding_grant_id":["2018RS3106, 2018SK50901, kq1801102, 2019-TJ-N04, 2019JJ50357, 2019SK4010, 2020JJ5340, 2020JJ3025"],"pubmed_authors":["Yang H","Lizaso A","Liu J","Liu L","Zeng L","Yang N","Xu Q","Hou T","Qiu L","Li Y","Zhang Y","Jiang W","Zhang X","Peng L"],"additional_accession":[]},"is_claimable":false,"name":"Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC.","description":"<h4>Background</h4>The combination of bevacizumab and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) could prolong progression-free survival (PFS) in patients with EGFR-mutant advanced non-small-cell lung cancer (NSCLC). Our study investigated the clinical and molecular factors that affect the efficacy of first-generation EGFR-TKI with or without bevacizumab and identify the subset of patients who can benefit from combination therapy.<h4>Methods</h4>Our study included 318 patients with EGFR-mutant locally advanced/advanced NSCLC treated with either first-generation EGFR-TKI combined with bevacizumab (A+T; n = 159) or EGFR-TKI monotherapy (T; n = 159). Two nomogram models to predict PFS and overall survival (OS), respectively, were constructed using two factors that","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-05-18T10:38:17.558Z","creation":"2025-05-18T10:38:17.558Z"},"accession":"S-EPMC8525046","cross_references":{"pubmed":["34663309"],"doi":["10.1186/s12916-021-02118-x"]}}